Hand transplants get a boost: new drug may reduce rejection risk

NCT ID NCT02310867

Recruiting now Disease control Sponsor: Linda Cendales Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tests whether a hand transplant from a deceased donor, combined with the immunosuppressant belatacept (Nulojix), can help people with below-elbow limb loss use their new hand in daily tasks. Fifty participants aged 18-65 will be followed for 18 months. The main goal is improved hand function, but risks include rejection, infection, and side effects from long-term anti-rejection drugs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Belatacept (Nulojix) plus hand transplant surgery
What this could lead to: If successful, this could offer a way for people with below-elbow limb loss to regain hand function for daily activities, using a new immunosuppressant to help prevent rejection.
What could go wrong: This is an early phase 2 study with only 50 participants, so results may not apply to everyone. Risks include organ rejection, serious infection, and side effects from long-term immunosuppression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNOSUPPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNOSUPPRESSION

Contacts and locations

Locations

Duke University Medical Center
RECRUITING

Durham, North Carolina, 27710, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.